Safety and durability of AGT103-T autologous T cell therapy for HIV infection in a Phase 1 trial.

Muvarak, Nidal; Li, Haishan; Lahusen, Tyler; Galvin, Jeffrey A; Kumar, Princy N; Pauza, C David; Bordon, José

Muvarak, Nidal; Li, Haishan; Lahusen, Tyler; Galvin, Jeffrey A; Kumar, Princy N; Pauza, C David; Bordon, José.

Afiliación

Muvarak N; American Gene Technologies International, Inc., Rockville, MD, United States.
Li H; American Gene Technologies International, Inc., Rockville, MD, United States.
Lahusen T; American Gene Technologies International, Inc., Rockville, MD, United States.
Galvin JA; American Gene Technologies International, Inc., Rockville, MD, United States.
Kumar PN; Georgetown University School of Medicine, Washington, DC, United States.
Pauza CD; American Gene Technologies International, Inc., Rockville, MD, United States.
Bordon J; Washington Health Institute, Washington, DC, United States.

Front Med (Lausanne) ; 9: 1044713, 2022.

Article en En | MEDLINE | ID: mdl-36452901

Palabras clave

HIV; cell therapy; functional cure; gene therapy; immune reconstitution

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Front Med (Lausanne) Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Suiza

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google